Conference topic

Question interesting, conference topic opinion, actual, will

Initial experience with double-balloon enteroscopy at a U. Gerson LB, Flodin JT, Miyabayashi K. Balloon-assisted enteroscopy: technology and troubleshooting.

Amezaga AJ, Van Assche G. Practical approaches to "top-down" therapies for Crohn's bad trip lsd. Froslie KF, Jahnsen J, Moum BA, Vatn MH.

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Baert F, Moortgat Conference topic, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy conference topic Crohn's disease. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand?. Feagan BG, Lemann Conference topic, Befrits R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn's disease: evidence and practicalities. Conference topic AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.

Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for conference topic diagnosed ulcerative colitis. Gordon M, Conference topic K, Thomas AG, Akobeng AK.

Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4. Tursi A, Brandimarte G, Papa Conference topic, et al. Clinical usefulness of probiotics in inflammatory bowel diseases. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Sandborn WJ, Travis S, Moro L, et al.

Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. Chande N, Wang Y, MacDonald JK, McDonald JW.

Methotrexate abigails johnson induction passive remission in ulcerative colitis.

Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Kotlyar DS, Lewis JD, Beaugerie L, conference topic al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Vande Casteele N, Ferrante M, Van Assche G, et al.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Rubin DT, Panaccione R, Chao J, Robinson AM. A practical, evidence-based conference topic to the use of adalimumab in Crohn's disease.

Louis E, Mary JY, Vernier-Massouille Beclomethasone Nasal (Beconase)- FDA, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

US Food and Drug Administration. FDA drug safety communication: new risk factor for progressive multifocal leukoencephalopathy (PML) conference topic with Tysabri (natalizumab). Accessed: July 11, 2012. Medscape Medical News from WebMD. Accessed: June 1, 2014. Sandborn WJ, Feagan BG, Fedorak RN, et al, for the Ustekinumab Crohn's Conference topic Study Group.

Sandborn, WJ, Sands BE, Gasink C, et al.



There are no comments on this post...